Use of substituted 2-aminotetralins for preventive treatment of parkinson's disease
The invention relates to the use of substituted 2-aminotetralins of general formula (I) as a medicament for the preventive treatment of Parkinson's disease.
1. A method for treatment of dopaminergic cell loss in a subject or decreasing the progression of Parkinson's disease in a subject, comprising
(a) identifying a subject without clinically confirmed Parkinson's disease; and
(b) administering to the subject rotigotine or a physiologically acceptable salt thereof.
2. The method of claim 1 , wherein the subject has at least one clinical symptom selected from the group consisting of an olfactory disorder, depression, a sleep disorder of the “REM behavior disorder” type, constipation and a short-term movement anomaly.
3. The method of claim 1 , wherein the subject displays a mutation in a PARK gene and/or a modification to alpha synuclein or neuromelanin pattern.
4. The method of claim 1 , wherein the subject displays a dopaminergic cell loss in substantia nigra of less than 60% before administering rotigotine.
5. The method of claim 1 , wherein the subject has a UPDRS motor score of less than 10 before administering rotigotine.
6. The method of claim 1 , wherein the subject has a Hoehn-Yahr score of 0 or 1.
7. The method of claim 1 , wherein rotigotine is administered parenterally, transdermally or mucosally.
8. The method of claim 1 , wherein rotigotine is administered in a dose of 0.05 to 50 mg per day.
9. The method of claim 1 , wherein the subject has one, two or three symptoms selected from the group consisting of rigor, resting tremor, bradykinesia and postural instability, to a partial degree.
10. A method for treatment of dopaminergic cell loss in a subject or decreasing the progression of Parkinson's disease in a subject, comprising
(a) identifying a subject without any of four cardinal symptoms of Parkinson's disease but having an increased risk of developing Parkinson's disease; and
(b) administering to the subject rotigotine or a physiologically acceptable salt thereof.
11. The method of claim 10 , wherein the subject displays a mutation in a PARK gene and/or a modification to alpha synuclein or neuromelanin pattern.
12. The method of claim 1 , wherein the subject displays a dopaminergic cell loss in substantia nigra of less than 50% before administering rotigotine.